Patient-oriented Research: Colon CA & Cancer Immunology

以患者为导向的研究：Colon CA

• 批准号: 7586771
• 负责人: RANDALL F HOLCOMBE
• 金额: $ 14.96万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-19 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7586771
• 关键词: Award; Biological Assay; Cancer Immunology Science; Clinical Research; Clinical Trials; Colon; Colon Carcinoma; Colorectal Cancer; Contracts; Correlative Study; Data; Dendritic Cells; Development; Diagnosis; Disease; Documentation; Event; Goals; Grapes; Hand; Hematology; Immune; Immune response; Immune system; Immunization; Immunologics; In Vitro; Inflammatory Bowel Diseases; Instruction; Interferons; Laboratories; Life Expectancy; Malignant Neoplasms; Measures; Mentors; Metastatic/Recurrent; Midcareer Investigator Award in Patient-Oriented Research; Monitor; Patients; Pilot Projects; Preventive; Research Ethics Committees; Resveratrol; Role; Signal Pathway; Skin; Therapeutic; Therapeutic Clinical Trial; Time; Translational Research; Work; Writing; base; chemotherapy; design; experience; high risk; improved; malignant stomach neoplasm; oncology; patient oriented research; peripheral blood; response; treatment strategy; tumor

This application is submitted as a competitive renewal of a midcareer investigator award in patient-oriented research (K24CA82450). The PI is Randall F. Holcombe, MD. This application details the experience, qualifications and short- and long-term patient-oriented research plans of Dr. Holcombe, as well as reviews progress during the period of support under the current award. Details about current and planned patient- oriented research is provided. These studies are focused on patient-oriented research in colon cancer and include studies related to the Wnt signaling pathway, elucidation of immunologic events in conjunction with administration of chemotherapy for colon cancer and definition of the mechanisms and potential therapeutic and cancer preventive effects of resveratrol, a naturally occuring compound found in the skin of grapes. Patients with inflammatory bowel disease, having or at high risk for colon cancer, are also studied. An additional clinical trial with laboratory correlative studies, originally designed and written by a mentee hematology-oncology fellow of Dr. Holcombe's involves the treatment of patients with gastric cancer. Mentoring activity over the past 5 years and mentoring plans for the next 5 years are described. The accomplishments of mentees are outlined as are their current activities, espeicially as related to ongoing participation in patient-oriented research. Ongoing mentoring plans include formal coursework, basic/translational research experiences, instruction in the development and implementation of clinical research trials, and hands-on experiences in clinical research. The original goals and objectives of the current award are reviewed and the extent to which these have been achieved is delineated. Documentation of institutional support and justification of the need for continued support through the K24 mechanism is provided.

本申请是作为以患者为中心的职业生涯中期研究者奖的竞争性更新而提交的 研究（K24CA82450）。 PI 是医学博士 Randall F. Holcombe。该应用程序详细介绍了体验， Holcombe 博士的资格和短期和长期以患者为中心的研究计划以及评论 在当前奖项的支持期间取得的进展。有关当前和计划患者的详细信息- 提供了定向研究。这些研究侧重于以患者为导向的结肠癌研究 包括与 Wnt 信号通路相关的研究、免疫事件的阐明以及 结肠癌化疗的施用及其机制和潜在治疗的定义 白藜芦醇的癌症预防作用，白藜芦醇是一种存在于葡萄皮中的天然化合物。 还对患有结肠癌或具有高风险结肠癌的炎症性肠病患者进行了研究。一个 额外的临床试验与实验室相关研究，最初由学员设计和编写 Holcombe 博士的血液肿瘤学研究员致力于胃癌患者的治疗。 描述了过去5年的指导活动和未来5年的指导计划。这 概述了受训者的成就以及他们当前的活动，特别是与正在进行的活动相关的 参与以患者为导向的研究。持续的指导计划包括正式的课程作业， 基础/转化研究经验、临床开发和实施的指导 研究试验和临床研究的实践经验。最初的目标和目标 对当前的奖励进行了审查，并描述了这些奖励已实现的程度。文档 机构支持的情况以及需要通过 K24 机制持续提供支持的理由 假如。